阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后,7月7日,其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据,为这家传统药企的细胞基因治疗布局注入强心剂。这项针对中国4例难治性多发性骨髓瘤患者的Ⅰ期试验结果显示,ESO-T01在单次静脉输注后即展现积极疗效:2例达到严格完全缓解(sCR),2例获得部分缓解(PR)。值得关注的是,受试患者均为经...
Source Link阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后,7月7日,其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据,为这家传统药企的细胞基因治疗布局注入强心剂。这项针对中国4例难治性多发性骨髓瘤患者的Ⅰ期试验结果显示,ESO-T01在单次静脉输注后即展现积极疗效:2例达到严格完全缓解(sCR),2例获得部分缓解(PR)。值得关注的是,受试患者均为经...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.